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ABSTRACT Based upon the observation that estrogen acts in the striatum to rapidly
modulate dopamine (DA) neural transmission and DA-mediated behaviors, it has been
postulated that these effects of estrogen are mediated by a specific, membrane-bound
receptor mechanism. To further characterize the pharmacological specificity of the estro-
gen binding site, the present experiments examine effects of various estrogen agonists on
amphetamine (AMPH)-induced DA release from striatal tissue of ovariectomized female
rats, using a superfusion method. Catechol estrogens 4-, and 2-hydroxyestradiol, but not
2-methoxyestradiol, significantly enhance AMPH-induced striatal DA release. Estrogen
metabolites, estrone and estriol, and the non-steroidal estrogen analog, diethylstilbes-
trol, are without effects. Estradiol conjugated to bovine serum albumin (BSA) mimics the
effect of estradiol to enhance stimulated striatal DA release. These results indicate that
the steroidal configuration and hydroxylation on the A-ring of estrogenic compounds may
be important determinants of ligand binding to the putative estrogen binding site in the
striatum. Furthermore, the effectiveness of the estradiol conjugated to BSA reinforces
the idea of an external membrane-bound receptor binding site in the striatum. Synapse
29:379–391, 1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
Accumulating evidence has demonstrated that estro-
gen can affect the neurochemical and behavioral indices
of dopaminergic activity in the striatum. For example,
estrogen treatments in ovariectomized (OVX) rats rap-
idly increase dopamine (DA) turnover (Di Paolo et al.,
1985), as well as striatal DA release in vivo and
associated behavior (Becker, 1990a; Castner et al.,
1993). Direct application of estrogen to the striatum
improves performance of OVX rats on a task that
requires sensorimotor coordination (Becker et al., 1987).
In vitro, estrogen at a physiologically relevant dose
stereospecifically potentiates K1- and amphetamine
(AMPH)-evoked DA release from striatal tissue of OVX
rats (Becker, 1990b). Most of these effects occur with a
more rapid onset and shorter duration than would be
expected if mediated by the classical estrogen receptor.
The mechanism by which estrogen exerts these seem-
ingly nongenomic effects is not fully understood as cells
in the striatum do not concentrate estrogen intracellu-
larly (Pfaff and Keiner, 1973; Simerly et al., 1990;
Stumpf and Sar, 1976). However, in addition to induc-
ing gene expression via the intracellular receptor, estro-
gen can produce specific effects through various mecha-
nisms, including specific binding to cell membranes
(Heritage et al., 1980; Liu and Patino, 1993; McEwen,
1979, 1994; Nabekura et al., 1986; Tischkau and
Ramirez, 1993; Towle and Sze, 1983; Wong and Moss,
1991). More recently, a study employing whole-cell
clamp recording has shown that 17b-estradiol (17b-E2)
at a very low dose (1–100 pM) inhibits L-type calcium
current in acutely dissociated striatal neurons. The
reduction of calcium current occurs within 100 millisec-
onds, and the 17a isomer is not as effective as 17b-E2
(Mermelstein et al., 1996). These data indicate that
estrogen acts directly in the striatum via a novel
estrogen receptor-mediated mechanism to enhance
striatal DA functions (Mermelstein et al., 1996). Fur-
thermore, 17b-E2 conjugated to bovine serum albumin,
which renders 17b-E2 membrane impermeable (Black-
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more et al., 1991; Ke and Ramirez, 1990; Zheng et al.,
1996), mimics the effect of 17b-E2 on the reduction of
calcium current (Mermelstein et al., 1996). Further-
more, this effect is prolonged when GTP-g-S is present
intracellularly to inhibit inactivation of the G-protein
complex (Mermelstein et al., 1996). These observations
suggest that the putative estrogen binding site may be
located on the extracellular surface of the cell mem-
brane and act via a G-protein-coupled mechanism
(Mermelstein et al., 1996).
The present experiments were designed to character-
ize the pharmacological specificity of the putative estro-
gen binding site in the striatum. To do so, several
agents known to be estrogen agonists and antagonists
at the classical estrogen receptor were examined for
their effectiveness on AMPH-stimulated DA release in
vitro. These compounds are of interest because they are
the biological metabolites of estradiol, with specific
modification in their chemical structures. For this
reason, they have been used as valuable tools to deci-
pher the mechanisms of estrogen actions at molecular,
physiological, and behavioral levels (Martucci and Fish-
man, 1976,1979; Merriam et al., 1980; Naish and Ball,
1981; Paul and Skolnick, 1977). From a pharmacologi-
cal point of view, information pertaining to configura-
tions of the hormone structure that are important for
the recognition of the hormone by the receptor will help
develop more specific pharmacological agents to facili-
tate isolation of the receptor.
MATERIALS AND METHODS
Animals
Adult female Spraque-Dawley rats weighing 180–
200 g upon arrival were purchased from Harland
Spraque Dawley Inc. (Indianapolis, IN), or raised at the
University of Michigan (Reproductive Sciences Pro-
gram, Ann Arbor, MI). They were housed 2–3 per cage
with food and water available all the time. Lighting was
maintained on a 14 hour light:10 hour dark schedule
(lights on at 0600 hour). All the animals were bilater-
ally ovariectomized under methoxyflurane anesthesia
2–3 weeks prior to superfusion experiments. Vaginal
lavage data were collected daily for at least 10 consecu-
tive days starting 5–7 days after ovariectomy. Only
animals that did not have cornified epithelial cells in
the vaginal smears during this time were included in
the experiments.
Superfusion Procedure
Superfusion experiments were performed using an
automated superfusion system (Brandel Inc., Gaithers-
burg, MD). A Ringer’s solution (145.0 mM NaCl, 2.7 mM
KCl2, 1.2 mM CaCl2, 1.0 MgCl2, 10.0 mM glucose, 0.25
mM ascorbic acid) was oxygenated by bubbling with
95% O2/5% CO2 for 30 minutes, and the pH was
adjusted to 7.4.
On the day of the superfusion experiment, animals
were decapitated, and the brain was quickly removed
and placed in ice-cold Ringer’s solution. The striatum
was dissected and a coronal slice of 3 mm thickness was
cut on an ice-cold rat brain slicer (Becker, 1990b).
Striatal tissue obtained from 9–10 animals was pooled,
cut into approximately 1 mm3 fragments, and placed
into superfusion chambers containing Ringer’s solu-
tion. Effluent samples were collected throughout the
treatment at 5-minute intervals in glass collection
vials. Following a 60-minute stabilization period with
Ringer’s, three baseline samples were collected. This
was followed by a period of 35-minute incubation with
solutions containing the tested compounds (see below
for details). Control chambers were run in parallel. A
2.5-min infusion of 10 µM d-amphetamine (AMPH) was
then delivered to all the chambers at the end of
incubation period. Additional 5-minute samples were
collected for 25 minutes following AMPH stimulation.
All media were continually infused into the chambers
at a flow rate of 100 µl/minute, and warmed to 370C in a
water bath prior to reaching the chambers. Each collec-
tion vial contained 25 µl of 0.05 N HClO4 with dihydroxy-
benzylamine (DHBA; final concentration 2 ng/ml) as an
internal standard to control for any variation in volume
and loss of DA due to oxidation. Striatal tissue in each
chamber was removed and weighed immediately follow-
ing the superfusion.
17b-E2 has been previously shown to potentiate
K1-induced striatal DA release most effectively at 100
pg/ml (370 pM) using this superfusion system (Becker,
1990b). Therefore, certain estrogen metabolites and
analogs were tested at concentrations equimolar to
the effective dose of 17b-E2. Higher or lower doses were
also used when the equimolar dose did not show a
significant effect. These compounds are depicted in
Figure 1. The doses tested are the following: catechol
estrogens 4-hydroxyestradiol (4-OHE2; 185 pM; 740
pM), 2-hydroxyestradiol (2-OHE2; 185 pM; 740 pM),
and 2-methoxyestradiol (2-MeE2; 210 pM; 2,100 pM);
estrogen metabolites estrone (210 pM; 2,100 pM) and
estriol (370 pM; 3,700 pM); the non-steroidal estrogen
analog diethylstilbestrol (DES; 370 pM; 1850 pM; 3,700
pM); and 17b-E2 covalently conjugated to bovine serum
albumin (E-BSA). Compounds (except E-BSA) were
dissolved in absolute ethanol as concentrated stocks
(3.7 mM) on the day of superfusion immediately prior to
striatal tissue preparation and then serially diluted to
their final concentrations. Final solutions of these
compounds all contained 0.001% ethanol, and this
concentration of ethanol has been found to have no
effects on basal or AMPH-induced striatal DA release.
For E-BSA, Ringer’s was used as vehicle and BSA as
the control solution. The concentration of E-BSA (510
pM) was calculated in a way so that the final solution
contained 100 pg/ml 17b-E2.
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Fig. 1. Chemical structures of the tested compounds and 17b-estradiol.
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DAAssay and Data Analysis
DA concentrations in the effluent samples were ana-
lyzed using a high performance liquid chromatography
system with electrochemical detection (HPLC-EC; ESA,
Chelmsford, MA). Baseline DA release was defined as
the mean DA release rate (pg/mg/min) of the first three
effluent samples. The mean DA release rate during
intervals following baseline, but prior to AMPH stimu-
lation (Pre-AMPH), was also determined. AMPH-
stimulated DA release (Post-AMPH) was expressed as a
percentage of the initial baseline. For each individual
experiment, a two-way analysis of variation (ANOVA)
with repeated measures (Time x Treatment) was per-
formed to compareAMPH-stimulated DArelease among
treatment groups. A one-way ANOVA was used to
determine whether there were group differences in DA
release rate during baseline, as well as during intervals
prior toAMPH stimulation. Post-hoc comparisons (Fish-
er’s PLSD) and Student’s t-tests were performed to
determine differences between specific treatment groups
if the ANOVA indicated a significant overall effect (P ,
0.05). All statistical analyses were performed on a
Macintosh computer using StatView 4.5.
Chemicals
The following compounds were obtained from
Sigma Chemicals (St. Louis, MO) or Steraloids Inc.
(Wilton, NH): 17b-E2, estrone, estriol, 2-hydroxyestra-
diol, 4-hydroxyestradiol, 2-methoxyestradiol, diethylstil-
bestrol (DES), 17b-E2 17-hemisuccinate:BSA (E-BSA),
and d-amphetamine. Methoxyflurance was purchased
from Pitman-Moore (Mundelein, IL).
RESULTS
Catechol Estrogens
Both of the catechol estrogens 4-OHE2 and 2-OHE2,
but not the methylated ether 2-MeE2, significantly
enhanced the AMPH-stimulated striatal DA release,
although with different potencies. The time course of
DA release from tissue treated with 740 pM and 185 pM
4-OHE2 or vehicle is presented in Figure 2. Treatment
Fig. 2. Time course of AMPH-induced DA release in vitro from
superfused striatal tissue fragments obtained from OVX rats. Follow-
ing a 60-minute equilibrium period, effluent samples were collected at
5-minute intervals. Values represent means 1 SEM (vertical bars) of
percentage of baseline, which was determined as the average of
effluent DA concentrations (pg/mg/min) in the first 3 samples. The
interval when an infusion of d-AMPH (10 µM) for 2.5 minutes was
given was designated as time 0. **Significant main effect of treatment
(P , .05) and effect of Treatment x Time interaction (P , .0005).
*Significantly different from Vehicle group (P , .03). †Significantly
different from 185 pM group (P , .05).
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with this compound resulted in a significant overall
effect of treatment (F2, 14 5 3.97, P , 0.05), and a
significant Treatment x Time interaction (F8, 56 5 4.31,
P , 0.0005). Post-hoc comparisons indicated greater
DA release in the group that received 185 pM (P , 0.02)
than in the control group (P , 0.02) or in the group that
received 740 pM (P 5 0.06). Further examination of
each Post-AMPH interval found that DA release from
striatal tissue treated with 185 pM 4-OHE2 was signifi-
cantly greater than that from vehicle-treated tissue at
10 minutes after AMPH stimulation and thereafter
(P , 0.03). It was also greater than that of the 740 pM
4-OHE2 group at 15 and 20 minutes (P , 0.05) following
AMPH.
2-OHE2 was less potent than 4-OHE2 in its effects on
AMPH-stimulated DA release from striatal tissue (Fig.
3). Treatments with this compound did not result in a
significant main effect (F2, 15 5 2.05, P . 0.09). How-
ever, there was a significant Treatment x Time interac-
tion (F8, 60 5 2.11, P , 0.05). This difference was
observed only at the first 5 minutes post-AMPH inter-
val where AMPH-induced DA release was greater after
740 pM 2-OHE2 than after treatment with 185 pM
2-OHE2 (P , 0.02) or vehicle (P , 0.05).
Figure 4 depicts the effect of 2-MeE2 on the striatal
DA release. Unlike the hydroxylated estradiol com-
pounds, this methylated catechol estrogen at concentra-
tions of 210 and 2,100 pM did not have any effect on DA
release elicited by AMPH (F2, 15 5 .37, P . 0.69). In
addition, in each of these experiments testing the
catechol estrogen compounds, there was no difference
in baseline or Pre-AMPH DA release among the treat-
ment groups (Table 1).
Estrogen Metabolites and a Non-Steroidal
Estrogen Analog
Neither of the estrogen metabolites, estrone or es-
triol, nor the non-steroidal estrogen analog DES showed
any significant estrogenic effect on AMPH-stimulated
DA release. As shown in Figure 5, DA release elicited by
AMPH from striatal tissue treated with 210 pM (Fig.
5A) or 2,100 pM (Fig. 5B) estrone did not differ from
that of the controls (F1, 6 5 .10, P . 0.70; F1, 9 5 .46, P .
Fig. 3. Time course of AMPH-induced DA release from striatal tissue treated with 2-OHE2 at 185 pM,
740 pM, or vehicle. Treatment procedure was the same as described in Figure 2. **Significant effect of
Time x Treatment interaction on AMPH-induced DA release among the groups (P , .05), which indicated
a significantly higher DA release by the higher dose of 2-OHE2 than both the lower dose and Vehicle
groups at 5 minutes following.
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0.50, respectively). Similarly, estriol at 370 or 3,700 pM
did not significantly affect the striatal DA release
induced by AMPH (F2, 6 5 1.20, P . 0.30; Fig. 6).
The results for the effect of DES on striatal DA
release are shown in Figure 7. At a concentration
equimolar to 100 pg/ml 17b-E2, DES failed to enhance
the AMPH-stimulated striatal DA release as compared
to the control (F1, 11 5 .01, P . 0.90; Fig. 7A). DES also
lacked any significant effect of enhancement even when
the concentration was at 5 or 10 times as high (F2, 15 5
1.08, P . 0.30; Fig. 7B). As in the case of experiments
with catechol estrogens, baseline DA or DA release
during exposure to estrone, estriol, or DES were not
different from that of the controls (Table 1).
Conjugated Estrogen
E-BSA significantly potentiated striatal DA release
induced by AMPH as compared to the control group
(F1, 37 5 4.80, P , 0.05; Fig. 8). This effect was seen in
the absence of any difference in basal or Pre-AMPH
striatal DA release (Table 1). Post-hoc tests indicated
Fig. 4. Time course of AMPH-induced striatal DA release showing the effect of 2-MeE2. Treatment
procedure was the same as described in Figure 2, but with 210 pM and 2.1 nM of 2-MeE2. There was no
significant difference observed.
TABLE I. Striatal dopamine release prior to AMPH





4-OHE2 (185 pM) 6 5.2 6 1.3 4.1 6 0.5
4-OHE2 (740 pM) 7 7.5 6 1.4 4.1 6 0.5
Vehicle 4 7.5 6 0.9 5.1 6 0.9
2-OHE2 (185 pM) 6 10.5 6 1.7 7.1 6 1.3
2-OHE2 (740 pM) 7 7.7 6 0.8 5.9 6 0.5
Vehicle 5 9.2 6 1.7 4.9 6 0.5
2-MeE2 (210 pM) 6 11.1 6 1.6 5.1 6 0.7
2-MeE2 (2.1 nM) 6 12.8 6 2.6 6.0 6 1.7
Vehicle 6 12.7 6 2.4 6.0 6 1.4
estrone (210 pM) 4 11.8 6 2.4 4.1 6 1.0
Vehicle 4 13.7 6 4.2 4.7 6 1.6
estrone (2.1 nM) 6 15.2 6 2.0 8.9 6 0.9
Vehicle 5 14.0 6 2.4 6.4 6 1.2
estriol (370 pM) 6 6.1 6 1.0 4.4 6 0.6
estriol (3.7 nM) 7 6.2 6 0.7 4.2 6 0.4
Vehicle 6 6.8 6 1.3 3.8 6 0.5
DES (370 pM) 8 12.0 6 1.7 6.4 6 1.1
Vehicle 5 1.9 6 1.4 6.2 6 0.3
DES (1.8 nM) 6 7.4 6 0.6 4.3 6 0.6
DES (3.7 nM) 6 6.4 6 0.5 4.5 6 0.5
Vehicle 6 6.9 6 1.1 5.2 6 0.5
E-BSA (510 pM) 22 6.6 6 0.7 6.1 6 1.3
BSA (410 pM) 17 7.2 6 0.6 4.9 6 0.6
1Mean 6 SEM of 3 baseline samples in pg/mg/min.
2Mean 6 SEM of DA release rate (pg/mg/min) during intervals when exposed to
the tested compounds or vehicle prior to AMPH stimulation.
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that in the first three, 5-minute intervals following
AMPH, the DA concentration in the effluent was signifi-
cantly enhanced by E-BSA treatment (P , 0.05).
DISCUSSION
The present results confirm and extend previous
findings from this laboratory and show that estrogen
exerts a rapid, steroid-specific action on striatal DA
neurotransmission. In particular, catechol estrogens
4-OHE2 and 2-OHE2, and the estrogen conjugate E-BSA
enhance AMPH-induced DA release from striatal tissue
of OVX rats. Methoxylated estradiol, 2-MeE2, estradi-
ol’s metabolites estrone and estriol, and the non-
steroidal estrogen DES did not have significant effects.
These results indicate that the enhancement by estro-
gen of striatal DA activity is likely to be mediated by a
Fig. 5. Effects of estrone at 210 pM (A) and 2.1 nM (B) on AMPH-induced striatal DA release. See
Figure 2 for superfusion procedures. None of the treatments with this compound induced a significant
effect on DA release.
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specific membrane binding site. Such an idea has been
reinforced by demonstrations of steroid binding sites on
neural membrane in other preparations (Majewska et
al., 1986; Ramirez et al., 1996; Towle and Sze, 1983),
and progesterone membrane binding sites in the stria-
tum (Ramirez et al., 1985, 1990, 1996; Ramirez and
Zheng, 1996). Furthermore, it suggests that hydrox-
ylation on the A-ring and the steroidal configuration
might be major factors that determine the affinity
and/or potency of the estrogen compounds at the bind-
ing site in the striatum (Fig. 1).
When looking for structural and chemical properties
of estrogens that might be relevant for the binding
specificity, the sterane ring structure characteristic of
all the steroids and the hydroxyl group(s) attached
should be considered. This is because these features are
helpful for comparing the membrane site with the
known properties of the intracellular estrogen receptor.
First, the two representative catechol estrogens, 4-OHE2
and 2-OHE2, are examined. Because of their natural
occurrence in the brain and the periphery, these two
compounds are believed to play important roles in the
hormonal regulation of endocrine and neuroendocrine
functions (Ball and Knuppen, 1990). Although both of
them are thought to be capable of interacting with the
classical estrogen receptor (Jellinck et al., 1981), there
are striking differences between the potencies of 2-OHE2
and 4-OHE2 (Ball and Knuppen, 1990). For example,
the uterotrophic effects of 4-OHE2 are indistinguish-
able from those of 17b-E2; whereas 2-OHE2 affects
uterine growth only as a weak estrogen (Franks et al.,
1982). In the pituitary, 4-OHE2 potently inhibits LH
levels, mimicking the effect of 17b-E2. 2-OHE2 fails to
do so, but is able to reverse the effect of 17b-E2 (Franks
et al., 1981). Similarly, 4-OHE2 is equipotent to 17b-E2,
while 2-OHE2 is ineffective, in the induction of proges-
tin binding sties in the hypothalamus, pituitary, and
the uterus of OVX rats (Kirchhoff et al., 1983). Thus,
hydroxylation of estradiol at C-2 vs. C-4 position can
differentially alter the physiological properties of estro-
gen.
Similar to their relative potencies at the classical
estrogen receptor, 4-OHE2 in the present experiment
appears to be a potent estrogen agonist. 2-OHE2 only
had marginal effects, and 2-MeE2 is not effective at all.
This relationship may be a result of the relative binding
affinity, as in the case for the intracellular estrogen
receptor. Merriam et al. (1980) have shown that 4-OHE2
binds as tightly as 17b-E2 to the cytosol estrogen
receptor in the hypothalamus, pituitary, and uterus.
2-OHE2 does less so, and 2-MeE2 shows no binding
affinity. These receptor affinities roughly parallel the
Fig. 6. Effects of estriol at 370 pM and 3.7 nM on AMPH-induced striatal DA release. See Figure 2 for
superfusion procedures. None of the concentrations of estriol significantly altered the time course of DA
release as compared to the control group.
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potencies of these compounds in altering gonadotro-
phin secretion (Franks et al., 1980; Martucci and
Fishman, 1979). For the intracellular estrogen recep-
tor, 2-hydroxylation derivatives have lower affinity to
the estrogen receptor than does 4-hydroxylation, and
methoxylation of the resultant catechol estrogens essen-
tially abolishes receptor binding activity (Martucci and
Fishman, 1979). Hence, the estrogen binding site in the
striatum seems to share some structural homology to
the intracellular estrogen receptor. Specifically, hydrox-
ylation at the A ring, especially at C-4 position, may be
critical for the ligand binding, and hence the efficacy of
the response. By contrast, C-2 hydroxylation and subse-
quent methoxylation attenuate the binding affinity.
Fig. 7. Effects of various doses of DES on AMPH-induced striatal DA release Treatment procedure
followed the description in Figure 2. DES at the 370 pM (A) was tested separately from the other two
higher doses of DES (1.85 and 3.7 nM; B). At all the doses tested, there was no significant difference
among treatment groups.
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In general, substitution of a 2- or 4-hydroxyl group on
the A-ring changes the biological properties of the
estrogen molecule: it not only alters the binding charac-
teristics of the molecule to the receptor, but also affects
the nature and extent of the possible interactions
between estrogen and catecholamine neurotransmitter
systems (Ghraf and Hiemke, 1983). As to the effects of
catechol estrogens on the DA neurotransmission de-
scribed above, a possibility remains that 2- and 4-OHE2
may interact directly with DA receptors in the stria-
tum. In fact, experimental evidence exists that catechol
estrogens are capable of binding to DA receptors. In the
anterior pituitary, Schaeffer and Hsueh (1979) have
demonstrated that 2-OHE2 potently inhibits [3H] spiro-
peridol binding to DA receptors in vitro. In the stria-
tum, 2-OHE2 was the most potent compound among the
steroids tested to compete for ligand binding to DA
receptors (Paden et al., 1982). However, in both cases,
17b-E2 is not effective in competing for DA receptors
binding. In the present experiments, 4-OHE2 exhibits
similar, potent effects to that of 17b-E2 on AMPH-
induced DA release (Becker, 1990b), whereas 2-OHE2
has only minor effects on the DA release. This order of
relative potency seems to conflict with the binding
activity to the DA receptors. Furthermore, modulation
by estrogen of AMPH-evoked striatal DA release has
been shown to be a presynaptic effect, as oppose to a
postsynaptic one (Becker and Beer, 1986). Therefore,
modulation of DA release by the effect of estrogenic
compounds on the estrogen binding site, rather than on
DA receptors, seems most likely to mediate the effect
reported. However, the present results do not eliminate
the possibility that estrogen interacts with DA autore-
ceptors to affect DA release.
It should be mentioned that the higher dose of
4-OHE2 appears to be less effective than the lower dose
at enhancing AMPH-induced DA release. A bell-shaped
dose response curve has also been observed in the effect
of 17b-E2 on KCl-stimulated striatal DA release using
the same superfusion procedure (Becker, 1990b). It is
possible that decreased efficacy at higher concentra-
tions of 4-OHE2 reflects the mechanism through which
estrogen interacts with its receptor and/or non-specific
effects on neuronal membranes (for discussion see
Becker, 1990b).
Most likely, at high concentrations non-specific inter-
actions between steroidal compounds and the cell mem-
brane are interfering with the efficacy of the hormone to
bind the receptor and/or interferring with the G-protein
effector system. That is, the hydrophobic nature of the
Fig. 8. Effects of E-BSA on AMPH-induced striatal DA release. Superfusion procedure followed the
description in Figure 2. **Main effect of treatment showing a significant difference between the two
groups (P , .05). *Significantly different from the control at 5, 10, and 15 minutes after stimulation with
AMPH (P , .05).
388 L. XIAO AND J.B. BECKER
steroids may allow them to intercalate with phospholip-
ids, thereby disrupting the organization of the lipid
bilayer of membrane (Wong et al., 1996). As a conse-
quence, we postulate that the functional properties of
membrane proteins, such as receptor binding or disso-
ciation of G-proteins within the membrane, are hin-
dered by an altered membrane structure.
In contrast to the potency of catechol estrogens,
neither estrone or estriol, the estrogens derived via
alternative metabolic pathways, show significant effect
on striatal DA release. These findings argue in favor of
the specificity and uniqueness of the effects of estrogen
on striatal DA release. Estrone, estradiol, and estriol
are equipotent uterotrophic agents when administered
in a continuous manner (Anderson et al., 1975; Miller,
1969), although estrone and estriol do not bind to the
cytosol estrogen receptor as tightly as estradiol in
uterus, pituitary and hypothalamus (Martucci and
Fishman, 1976; Merriam et al., 1980). These differences
suggest that the membrane estrogen binding site in the
striatum may differ from the intracellular estrogen
receptor at least in the ligand structural requirement
for D ring. Modifications at C-16 or C-17 may attenuate
the binding affinity, leading to a lack of response. It is
also possible that estrone and estriol bind to the
receptor with similar affinities as E2, but are unable to
induce an effect due to the transient receptor occupancy
(Anderson et al., 1972, 1975). However, it has been
suggested that the addition of a hydroxyl group at C-16
is important for the ligand binding to the membrane
binding site in the striatum. This is because estriol, but
not estrone, is as effective as 17b-E2 in the inhibition of
L-type calcium current in striatal neurons (Mermel-
stein et al., 1996). The differences in the mode of
hormone administration and the sensitivity of the
physiological response examined may have to be consid-
ered to account for the discrepancy in these results.
The most distinct feature of the membrane binding
site in the striatum may have to do with the steroidal
specificity, as demonstrated by the effects of DES on
striatal DA release. DES is a potent, non-steroidal
estrogen analog in the uterus that induces uterine
growth (Branham et al., 1993; Grunert et al., 1986). It
also mimics estrogen in the hypothalamus and pitu-
itary to regulate hormone secretion (Halling, 1992;
Jordan and Lieberman, 1984). These effects are medi-
ated by the intracellular estrogen receptor since DES
resembles 17b-E2 in uterine nuclear estrogen receptor
binding (Attardi and Happe, 1986). In the present
experiment, however, DES fails to exhibit any estro-
genic effect, even at high doses. This suggests that the
steroidal structures of estrogenic compounds are criti-
cal for the enhancement on striatal DA release. DES
has also been found to act as an estrogen antagonist
when interacting with non-genomic estrogen receptors
in guinea pig hypothalamus neurons (Lagrange et al.,
1997). 17b-E2 rapidly attenuates µ-opioid-induced hy-
perpolarization. DES blocks the nongenomic effect of
estrogen without showing E2-like response (Lagrange
et al., 1997). Whether DES is an estrogen antagonist in
the striatum remains to be determined. However, the
fact that it does not mimic the effect of estrogen on
AMPH-induced striatal DA release supports the idea
that the receptor binding site is distinct from the
intracellular estrogen receptor in the uterus with re-
spect to the steroidal specificity.
There are at least two pieces of direct evidence
supporting the idea that effects reported are mediated
by a membrane receptor for estrogen in the striatum:
(1) estradiol conjugated to BSA is as effective as estra-
diol at enhancing AMPH-induced DA release in the
present experiment; and (2) E-BSA is as effective as
17b-E2 in inhibiting the L-type calcium current in
striatal neurons (Mermelstein et al., 1996). The ques-
tion of whether the effect of E-BSA in the striatum is
mediated by a small amount of estrogen that has
dissociated from the BSA and can diffuse into the cell
does seem particularly germane in this system, as cells
with classical estrogen receptors are not found in the
striatum (Pfaff and Keiner, 1973; Simerly et al., 1990).
Furthermore, in whole cell-clamp experiments with
100 pM estradiol in the recording electrode, which
dialyzes with the contents of the cell to produce a
concentration of 100 pM 17b-E2 inside the cell, 1 pM
17b-E2 is still effective at producing a decrease in
L-type calcium current when applied extracellularly,
arguing that the effect of estradiol in the striatum is
extracellular (Mermelstein et al., 1996). Finally, a
membrane-associated estrogen binding site has been
demonstrated in the striatum (Zheng et al., 1996).
Using E-BSA, Zheng and colleagues have been able to
show a specific membrane binding site in synaptosomal
membrane preparations from the cerebellum, hypo-
thalamus, olfactory bulb, and corpus striatum (Zheng
et al., 1996). These experiments lend support to the
assumption that estrogen is acting at an extracellular
membrane binding site, rather than the classical intra-
cellular estrogen.
In conclusion, the results presented here support the
idea that estrogenic compounds rapidly modulate
AMPH-induced striatal DA release via a steroid-
specific, membrane-associated receptor mechanism(s).
This effect appears to be influenced by two main factors:
(1) the position of constituents added to the basic
estrogen ring structure, with hydroxylation on the A
ring being more effective than modifications on the D
ring, and (2) the 3-D configuration of the receptor
binding site, which appears to require a rigid steroidal
ring structure for receptor activation. These results are
important for two reasons. First, they demonstrate the
pharmacological differences between estrogen recep-
tors in the striatum and the classical estrogen receptor,
and may help in the eventual isolation and cloning of
the receptor. Second, these results may be important for
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our understanding of how hormone replacement therapy
(HRT) can produce different psychological effects de-
pending on the drug used. Premarint is one of the more
widely prescribed HRT drugs, and contains high concen-
trations of estrone, as well as other estrogen metabo-
lites in lower concentrations, but does not contain
17b-E2. So, enhanced striatal DA activity or sensorimo-
tor function are not likely to be an effect of Premarint
treatment if, in fact, the positive effects of estrogen on
sensorimotor function in humans (Hampson, 1990) are
mediated by the mechanism under investigation here.
As we come to understand the variety of mechanisms
through which estrogenic compounds can interact with
the brain and peripheral tissues, our ability to target
specific subsets of receptors may lead to significant
improvements in HRT.
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